The poster presentation provides clinical data from a Phase 1 dose escalation and expansion study of bemcentinib (BGB324) in combination with docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC). The data presented indicate that bemcentinib in combination with docetaxel shows evidence of anti-tumor activity, with 35% of patients achieving a partial response and 47% attaining stable disease, and a manageable safety profile in previously treated, advanced NSCLC.
The full abstract is available on the ASCO website here: https://meetings.asco.org/abstracts-presentations/212839
Full details of the presentation are below:
Title: Phase 1 dose escalation and expansion study of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced NSCLC.
Author: Bhalla et al.
Session/Abstract ID:
Location/Time:
Contacts:
ir@bergenbio.com
rune.skeie@bergenbio.com
International Media Relations
bergenbio@consilium-comms.com
+44 20 3709 5700
About
Forward looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties, and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
https://news.cision.com/bergenbio-asa/r/bergenbio-presents-clinical-data-on-bemcentinib-in-combination-with-docetaxel-in-patients-with-previ,c3580760
https://mb.cision.com/Main/15728/3580760/1589275.pdf
(c) 2022 Cision. All rights reserved., source